• Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  
• Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
  

PubMed=16885381; DOI=10.1158/0008-5472.CAN-05-3984
Macedo L.F., Guo Z.-Y., Tilghman S.L., Sabnis G.J., Qiu Y., Brodie A.M.H.
Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole.
Cancer Res. 66:7775-7782(2006)

PubMed=17942301; DOI=10.1016/j.jsbmb.2007.04.005
Sabnis G.J., Macedo L.F., Goloubeva O., Schayowitz A.B., Zhu Y., Brodie A.M.H.
Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model.
J. Steroid Biochem. Mol. Biol. 108:1-7(2008)

PubMed=22659283; DOI=10.1016/j.jsbmb.2012.05.008
Schech A.J., Nemieboka B.E., Brodie A.M.H.
Zoledronic acid inhibits aromatase activity and phosphorylation: potential mechanism for additive zoledronic acid and letrozole drug interaction.
J. Steroid Biochem. Mol. Biol. 132:195-202(2012)

PubMed=24472707; DOI=10.1186/bcr3609
Kazi A.A., Gilani R.A., Schech A.J., Chumsri S., Sabnis G.J., Shah P., Goloubeva O., Kronsberg S.S., Brodie A.M.H.
Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
Breast Cancer Res. 16:R15.1-R15.18(2014)